A Randomized, Double-Masked, Placebo-Controlled Phase 1/2a Study of the Efficacy and Safety of Two Dosing Regimens of RVL-1201 in the Treatment of Acquired Blepharoptosis
Latest Information Update: 18 Nov 2021
At a glance
- Drugs Oxymetazoline (Primary)
- Indications Blepharoptosis
- Focus Therapeutic Use
- Sponsors RevitaLid; RVL
- 17 Feb 2014 New trial record